Why insider trading matters?
When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.
AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. AxoGen, Inc. is headquartered in Alachua, Florida.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2022-08-10 | Freitag Gregory Gene | Director | Sell | 8,886 | $9.70 | $86,159 | No |
| 2021-08-10 | Zaderej Karen L. | CEO | Sell | 41,000 | $18.47 | $757,194 | Yes |
| 2021-02-25 | Freitag Gregory Gene | Director | Sell | 24,000 | $22.06 | $529,440 | No |
| 2021-02-18 | Donovan Michael Patrick | VP Operations | Sell | 1,808 | $19.15 | $34,623 | No |
| 2021-01-08 | Zaderej Karen L. | CEO | Sell | 65,000 | $20.00 | $1,300,000 | No |
| 2020-12-30 | Donovan Michael Patrick | VP Operations | Sell | 1,733 | $17.48 | $30,293 | No |
| 2020-12-29 | DeVinney Erick Wayne | VP, Clinical&Translational Sc | Sell | 371 | $17.81 | $6,608 | No |
| 2020-12-29 | Donovan Michael Patrick | VP Operations | Sell | 567 | $17.81 | $10,098 | No |
| 2020-12-29 | Freitag Gregory Gene | Director | Sell | 916 | $17.81 | $16,314 | No |
| 2020-12-29 | MARIANI PETER J | Chief Financial Officer | Sell | 1,293 | $17.81 | $23,028 | No |
| 2020-12-29 | Scopelianos Angelo | VP Research & Development | Sell | 567 | $17.81 | $10,098 | No |
| 2020-12-29 | Zaderej Karen L. | CEO | Sell | 3,500 | $17.81 | $62,335 | No |
| 2020-12-29 | Friedman Mark Louis | VP, Regulatory & Quality | Sell | 567 | $17.81 | $10,098 | No |
| 2020-12-29 | MARTINEZ MARIA D. | Chief Human Resources Officer | Sell | 567 | $17.81 | $10,098 | No |
| 2020-12-29 | Billet Isabelle | Chief Strategy and BD Officer | Sell | 649 | $17.81 | $11,559 | No |
| 2020-12-22 | Donovan Michael Patrick | VP Operations | Sell | 279 | $17.19 | $4,796 | No |
| 2020-12-21 | Zaderej Karen L. | CEO | Sell | 1,275 | $16.42 | $20,936 | No |
| 2020-12-21 | DeVinney Erick Wayne | VP, Clinical&Translational Sc | Sell | 147 | $16.42 | $2,414 | No |
| 2020-12-21 | Freitag Gregory Gene | Director | Sell | 379 | $16.42 | $6,223 | No |
| 2020-12-21 | Donovan Michael Patrick | VP Operations | Sell | 96 | $16.42 | $1,576 | No |
| 2020-12-21 | MARIANI PETER J | Chief Financial Officer | Sell | 481 | $16.42 | $7,898 | No |
| 2020-12-21 | Friedman Mark Louis | VP, Regulatory & Quality | Sell | 96 | $16.42 | $1,576 | No |
| 2020-11-09 | Donovan Michael Patrick | VP Operations | Sell | 17,617 | $15.00 | $264,255 | No |
| 2020-11-09 | Zaderej Karen L. | CEO | Sell | 14,000 | $14.53 | $203,420 | No |
| 2020-10-30 | MARIANI PETER J | Chief Financial Officer | Sell | 75,683 | $12.41 | $939,353 | Yes |
| 2019-08-12 | Blackford Quentin S. | Director | Buy | 15,535 | $14.01 | $217,672 | No |
| 2019-08-09 | Gold Mark Stephen | Director | Buy | 4,000 | $13.10 | $52,389 | No |
| 2019-08-13 | Billet Isabelle | Chief Strategy and BD Officer | Buy | 5,635 | $15.11 | $85,139 | No |
| 2019-08-14 | MARTINEZ MARIA D. | Chief Human Resources Officer | Buy | 2,000 | $15.13 | $30,260 | No |
| 2019-08-12 | Blackford Quentin S. | Director | Buy | 15,535 | $14.01 | $217,672 | No |
Insider Smart
Insider Smart